Savithri Rajkumar1, Rahul Nath2, Geoffrey Lane2, Gautam Mehra2, Shahina Begum3, Ahmad Sayasneh4. 1. Department of Gynaecological Oncology, Guy's and St Thomas' Hospital NHS Foundation Trust (GSTT), Westminster Bridge Road, London, SE1 7EH, United Kingdom. Electronic address: savithri14@gmail.com. 2. Department of Gynaecological Oncology, Guy's and St Thomas' Hospital NHS Foundation Trust (GSTT), Westminster Bridge Road, London, SE1 7EH, United Kingdom. 3. Department of Women and Children's Health, School of Life Course Sciences, King's College London & King's Health Partners, St Thomas' Hospital, London, SE1 7EH, United Kingdom. 4. Department of Gynaecological Oncology, Guy's and St Thomas' Hospital NHS Foundation Trust (GSTT), Westminster Bridge Road, London, SE1 7EH, United Kingdom; School of Life Course Sciences, Faculty of Life Sciences and Medicine, King's College London, Guy's Campus, St Thomas Street, London, SE1 9RT, United Kingdom.
Abstract
OBJECTIVE: Primary aim of this study was to assess the impact of optimal cytoreduction in women who had surgical treatment of advanced stage (IIIC/IV) endometrial cancer. Secondary objective was to define demographic and surgico-pathologic variables that exerted a significant influence on survival outcomes. STUDY DESIGN: Records of 45 patients with stage IIIC/IV Endometrial cancer who underwent surgery with cytoreductive intent between 2010 and 2016 were analysed. Data on disease distribution, surgical procedures, adjuvant therapy and survival times was collated. Survival curves were plotted by Kaplan Meier method and median survival estimates were compared using log rank test. Cox proportional hazards model was used to identify independent variables predictive of survival. RESULTS: 28 women (62.2%) had undergone primary surgery and 17 (37.8%) received neoadjuvant chemotherapy prior to delayed primary surgery. Optimal cytoreduction to </ = 1 cm visible disease was achieved in 29 women (64.4%). Among 29 women who had optimal debulking, 24 had no visible disease. Median overall survival for the entire study cohort was 24 months. Median progression free survival in the optimal cytoreduction group was 16 months as opposed to 11.5 months in women who had > 1 cm residual disease (p = 0.02). Median overall survival was 29 months in patients who had optimal cytoreduction and 17.5 months in women who had bulky residual disease (p=0.002). Only poor performance status (p = 0.035), presence of bowel disease (p = 0.05) and suboptimal cytoreduction (p = 0.006) retained significance as predictors of poor survival on multivariate analyses. Suboptimal cytoreduction surgery, compared to optimal cytoreduction, showed a 3.55-fold increased risk of death independent of performance status and anatomic region with disease (Hazard Ratio 3.55 (95% confidence interval 1.44-8.73) p = 0.006). CONCLUSION: Survival analyses demonstrate significantly better progression free survival and overall survival when optimal cytoreduction is achieved. A prospective, multicentre study is recommended to establish conclusive evidence. Crown
OBJECTIVE: Primary aim of this study was to assess the impact of optimal cytoreduction in women who had surgical treatment of advanced stage (IIIC/IV) endometrial cancer. Secondary objective was to define demographic and surgico-pathologic variables that exerted a significant influence on survival outcomes. STUDY DESIGN: Records of 45 patients with stage IIIC/IV Endometrial cancer who underwent surgery with cytoreductive intent between 2010 and 2016 were analysed. Data on disease distribution, surgical procedures, adjuvant therapy and survival times was collated. Survival curves were plotted by Kaplan Meier method and median survival estimates were compared using log rank test. Cox proportional hazards model was used to identify independent variables predictive of survival. RESULTS: 28 women (62.2%) had undergone primary surgery and 17 (37.8%) received neoadjuvant chemotherapy prior to delayed primary surgery. Optimal cytoreduction to </ = 1 cm visible disease was achieved in 29 women (64.4%). Among 29 women who had optimal debulking, 24 had no visible disease. Median overall survival for the entire study cohort was 24 months. Median progression free survival in the optimal cytoreduction group was 16 months as opposed to 11.5 months in women who had > 1 cm residual disease (p = 0.02). Median overall survival was 29 months in patients who had optimal cytoreduction and 17.5 months in women who had bulky residual disease (p=0.002). Only poor performance status (p = 0.035), presence of bowel disease (p = 0.05) and suboptimal cytoreduction (p = 0.006) retained significance as predictors of poor survival on multivariate analyses. Suboptimal cytoreduction surgery, compared to optimal cytoreduction, showed a 3.55-fold increased risk of death independent of performance status and anatomic region with disease (Hazard Ratio 3.55 (95% confidence interval 1.44-8.73) p = 0.006). CONCLUSION: Survival analyses demonstrate significantly better progression free survival and overall survival when optimal cytoreduction is achieved. A prospective, multicentre study is recommended to establish conclusive evidence. Crown
Authors: Nicole Concin; Carien L Creutzberg; Ignace Vergote; David Cibula; Mansoor Raza Mirza; Simone Marnitz; Jonathan A Ledermann; Tjalling Bosse; Cyrus Chargari; Anna Fagotti; Christina Fotopoulou; Antonio González-Martín; Sigurd F Lax; Domenica Lorusso; Christian Marth; Philippe Morice; Remi A Nout; Dearbhaile E O'Donnell; Denis Querleu; Maria Rosaria Raspollini; Jalid Sehouli; Alina E Sturdza; Alexandra Taylor; Anneke M Westermann; Pauline Wimberger; Nicoletta Colombo; François Planchamp; Xavier Matias-Guiu Journal: Virchows Arch Date: 2021-02 Impact factor: 4.064
Authors: Lea A Moukarzel; Maureen E Byrne; Stephanie Leiva; Michelle Wu; Qin C Zhou; Alexia Iasonos; Nadeem R Abu-Rustum; Yukio Sonoda; Ginger Gardner; Mario M Leitao; Vance A Broach; Dennis S Chi; Kara Long Roche; Oliver Zivanovic Journal: Gynecol Oncol Date: 2020-05-24 Impact factor: 5.482
Authors: Nadeem R Abu-Rustum; Roberto Angioli; Arthur E Bailey; Vance Broach; Alessandro Buda; Michelle R Coriddi; Joseph H Dayan; Michael Frumovitz; Yong Man Kim; Rainer Kimmig; Mario M Leitao; Mustafa Zelal Muallem; Matt McKittrick; Babak Mehrara; Roberto Montera; Lea A Moukarzel; Raj Naik; Silvana Pedra Nobre; Marie Plante; Francesco Plotti; Oliver Zivanovic Journal: Int J Gynecol Cancer Date: 2020-03-30 Impact factor: 3.437
Authors: Allan B Huang; Jenny Wu; Ling Chen; Benjamin B Albright; Rebecca A Previs; Haley A Moss; Brittany A Davidson; Laura J Havrilesky; Alexander Melamed; Jason D Wright Journal: Gynecol Oncol Rep Date: 2021-11-06
Authors: Jason D Wright; Yongmei Huang; Alexander Melamed; Benjamin B Albright; Grace C Hillyer; Rebecca Previs; M S Dawn L Hershman Journal: Gynecol Oncol Date: 2021-06-20 Impact factor: 5.304
Authors: Khalid H Sait; Mohammad Z Alam; Absarul Haque; Hesham K Sait; Maram K Sait; Nisreen M Anfinan Journal: Saudi Med J Date: 2022-02 Impact factor: 1.422